OSLO, Norway, Oct. 24, 2019 /PRNewswire/ -- Reference is made
to the stock exchange announcement on 18
October 2019 where Nordic Nanovector ASA (OSE: NANO) (the
"Company") announced the successful completion of a private
placement raising gross proceeds of NOK
242,525,624 (the "Private Placement") and that the board of
directors would consider to carry out a repair offering of up to
2,204,778 new shares (the "Repair Offering").
The Company has decided not to proceed with the Repair Offering.
Since announcement of completion of the Private Placement on
18 October 2019, the Company's shares
have traded on the Oslo Stock Exchange, with sufficient trading
volume, at prices close to or below the subscription price in the
Private Placement of NOK 22.
Accordingly, any shareholders wishing to neutralize the dilutive
effect of the Private Placement have had the opportunity to
purchase shares in the Company in the market, at prices close to or
below what would have been the subscription price in a Repair
Offering. In light of this, the Company has resolved not to proceed
with a Repair Offering that would have resulted in considerable
preparation costs for the Company.
For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---resolution-not-to-proceed-with-a-repair-offering,c2940120